An Average Patient In A Clinical Trial Isn't An Average Patient In Real Life. And That's A Problem.

Those who sign up for clinical trials tend to be younger, whiter and healthier than other cancer patients, which is causing a dissonance between the success of a drug in trials and its success in real life.